Sutro Biopharma, Inc. (STRO)

US — Healthcare Sector
Peers: PCVX  LRMR  SNDX  MRUS  IDYA  ANAB  MGTX  KROS  FIXX  NAMSW  CNTA  OPT  HLVX  GLSH  ELYM  GNTA  PRDS  AVTE  MLYS  REPL 

Automate Your Wheel Strategy on STRO

With Tiblio's Option Bot, you can configure your own wheel strategy including STRO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol STRO
  • Rev/Share 0.7994
  • Book/Share -0.3106
  • PB -2.8904
  • Debt/Equity -0.829
  • CurrentRatio 2.1602
  • ROIC -1.2889

 

  • MktCap 75820999.0
  • FreeCF/Share -2.3886
  • PFCF -0.382
  • PE -0.3042
  • Debt/Assets 0.0666
  • DivYield 0
  • ROE -3.4759

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade STRO H.C. Wainwright Buy Neutral -- -- March 17, 2025
Downgrade STRO BofA Securities Buy Underperform $11 $1 March 14, 2025
Downgrade STRO Citizens JMP Mkt Outperform Market Perform -- -- March 14, 2025
Downgrade STRO Wedbush Outperform Neutral $8 $2 March 14, 2025

News

Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline
STRO
Published: March 14, 2025 by: Benzinga
Sentiment: Negative

On Thursday, Sutro Biopharma, Inc. STRO prioritized its antibody-drug conjugates (ADC) pipeline, including three wholly-owned preclinical programs in its next-generation ADC pipeline.

Read More
image for news Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline

About Sutro Biopharma, Inc. (STRO)

  • IPO Date 2018-09-27
  • Website https://www.sutrobio.com
  • Industry Biotechnology
  • CEO Ms. Jane Chung R.Ph.
  • Employees 269

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.